Grundläggande statistik
| CIK | 1059790 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Pozen, Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| March 14, 2016 |
March 14, 2016 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: POZEN Inc. Withdrawal of Registration Statement on Form S-3 (File No. 333-201948) Ladies and Gentlemen: Pursuant to Rule 477 promulgated under the Securities Act of 1933, as amended (the ?Securities Act?), POZEN Inc. (the ?Registrant?) hereby respectfully re |
|
| March 14, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 000-31719 POZEN INC. (Exact name of registrant as specified in its charter) |
|
| March 14, 2016 |
As filed with the Securities and Exchange Commission on March 14, 2016 Registration No. |
|
| February 10, 2016 |
POZN / Pozen, Inc. / PAR INVESTMENT PARTNERS LP - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* Pozen, Inc. (Name of Issuer) Common stock, par value $.01 (Title of Class of Securities) 73941U102 (CUSIP Number) February 5, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 5, 2016 |
SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION POZEN INC. EXHIBIT 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF POZEN INC. POZEN Inc., a corporation organized and existing under the laws of the State of Delaware, hereby certifies as follows: A. The name of the Corporation is POZEN Inc. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on September 25, 1996 and ame |
|
| February 5, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 5, 2016 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of incorporation) (Commission File Number |
|
| February 5, 2016 |
EXHIBIT 99.1 POZEN AND TRIBUTE COMBINE TO CREATE ARALEZ PHARMACEUTICALS INC. -Transformative Transaction Creates Premier Specialty Pharma Company with a Broad Product Portfolio- -Canadian Domicile Provides Compelling Platform for Growth with Competitive Structure- -US$350 Million Capital Commitment from Deerfield-Led Syndicate- MILTON, Ontario ? February 5, 2016 ? Aralez Pharmaceuticals Inc. (?Ara |
|
| February 2, 2016 |
Exhibit 99.1 POZEN INC. ANNOUNCES STOCKHOLDER APPROVAL OF ITS TRANSACTION WITH TRIBUTE PHARMACEUTICALS CANADA INC. -Transaction Expected to Close on or About February 5, 2016- CHAPEL HILL, NC ? February 2, 2016, POZEN Inc. (?POZEN?) (NASDAQ: POZN), a specialty pharmaceutical company, today announced that its stockholders approved the Agreement and Plan of Merger and Arrangement (the ?Merger Agreem |
|
| February 2, 2016 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2016 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of incorporation) (Commission File Number |
|
| January 19, 2016 |
POZN / Pozen, Inc. / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* POZEN INC. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 73941U102 (CUSIP Number) January 15, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| January 19, 2016 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| December 28, 2015 |
Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 TABLE OF CONTENTS 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 28, 2015 |
EX-99.1 2 a15-248006ex99d1.htm EX-99.1 Exhibit 99.1 Filed pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to 14a-12 under the Securities Exchange Act of 1934, as amended Filing Person: POZEN Inc. Commission File No.: 000-31719 POZEN ANNOUNCES EFFECTIVENESS OF ARALEZ REGISTRATION STATEMENT ON FORM S-4 AND PROVIDES UPDATE ON KEY MILESTONES FOR 2016 -POZEN |
|
| December 28, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| December 28, 2015 |
EX-99.1 2 a15-248006ex99d1.htm EX-99.1 Exhibit 99.1 Filed pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to 14a-12 under the Securities Exchange Act of 1934, as amended Filing Person: POZEN Inc. Commission File No.: 000-31719 POZEN ANNOUNCES EFFECTIVENESS OF ARALEZ REGISTRATION STATEMENT ON FORM S-4 AND PROVIDES UPDATE ON KEY MILESTONES FOR 2016 -POZEN |
|
| December 28, 2015 |
425 1 a15-2480068k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of incorporat |
|
| December 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| December 14, 2015 |
425 1 a15-2500618k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of incorporat |
|
| December 8, 2015 |
AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF MERGER AND ARRANGEMENT EX-2.2 3 a15-245881ex2d2.htm EX-2.2 Exhibit 2.2 AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF MERGER AND ARRANGEMENT This AMENDMENT NO. 2 (this “Amendment”) to the Agreement and Plan of Merger and Arrangement is made as of December 7, 2015, by and among Tribute Pharmaceuticals Canada Inc., a corporation formed under the laws of the Province of Ontario, Canada (“Tribute”), Aralez Pharmaceuticals plc, a |
|
| December 8, 2015 |
Financial Statements and Exhibits, Other Events, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of incorporation) (Commission File Number |
|
| December 8, 2015 |
Exhibit 2.2 AMENDMENT NO. 2 TO AGREEMENT AND PLAN OF MERGER AND ARRANGEMENT This AMENDMENT NO. 2 (this Amendment) to the Agreement and Plan of Merger and Arrangement is made as of December 7, 2015, by and among Tribute Pharmaceuticals Canada Inc., a corporation formed under the laws of the Province of Ontario, Canada (Tribute), Aralez Pharmaceuticals plc, a public limited company formed under |
|
| December 8, 2015 |
AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER AND ARRANGEMENT Exhibit 2.1 AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER AND ARRANGEMENT AMENDMENT NO. 1, dated as of August 19, 2015 (this ?Amendment?), to the Agreement and Plan of Merger and Arrangement, dated as of June 8, 2015 (the ?Merger Agreement?), by and among Tribute Pharmaceuticals Canada Inc., a corporation incorporated under the laws of the Province of Ontario (?Tribute?), Aguono Limited, a priva |
|
| December 8, 2015 |
Exhibit 2.1 AMENDMENT NO. 1 TO AGREEMENT AND PLAN OF MERGER AND ARRANGEMENT AMENDMENT NO. 1, dated as of August 19, 2015 (this ?Amendment?), to the Agreement and Plan of Merger and Arrangement, dated as of June 8, 2015 (the ?Merger Agreement?), by and among Tribute Pharmaceuticals Canada Inc., a corporation incorporated under the laws of the Province of Ontario (?Tribute?), Aguono Limited, a priva |
|
| December 8, 2015 |
EX-10.1 4 a15-245881ex10d1.htm EX-10.1 Exhibit 10.1 SECOND AMENDED AND RESTATED FACILITY AGREEMENT This SECOND AMENDED AND RESTATED FACILITY AGREEMENT (this “Agreement”), dated as of December 7, 2015, by and among Aralez Pharmaceuticals Inc., a corporation formed under the laws of the Province of British Columbia, Canada (“Parent”), POZEN Inc., a corporation formed under the laws of the State of D |
|
| December 8, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 7, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of incorporation) (Commission File Number |
|
| December 8, 2015 |
EX-10.1 4 a15-245881ex10d1.htm EX-10.1 Exhibit 10.1 SECOND AMENDED AND RESTATED FACILITY AGREEMENT This SECOND AMENDED AND RESTATED FACILITY AGREEMENT (this “Agreement”), dated as of December 7, 2015, by and among Aralez Pharmaceuticals Inc., a corporation formed under the laws of the Province of British Columbia, Canada (“Parent”), POZEN Inc., a corporation formed under the laws of the State of D |
|
| November 23, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| November 23, 2015 |
Exhibit 99.1 Filed pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to 14a-12 under the Securities Exchange Act of 1934, as amended Filing Person: POZEN Inc. Commission File No.: 000-31719 POZEN AND TRIBUTE PROVIDE UPDATE ON PENDING COMBINATION TRANSACTIONS -POZEN and Tribute Evaluating Canadian Domicile for Aralez Pharmaceuticals- CHAPEL HILL, NC and MI |
|
| November 23, 2015 |
EX-99.1 2 a15-239141ex99d1.htm EX-99.1 Exhibit 99.1 Filed pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to 14a-12 under the Securities Exchange Act of 1934, as amended Filing Person: POZEN Inc. Commission File No.: 000-31719 POZEN AND TRIBUTE PROVIDE UPDATE ON PENDING COMBINATION TRANSACTIONS -POZEN and Tribute Evaluating Canadian Domicile for Aralez |
|
| November 23, 2015 |
Financial Statements and Exhibits, Other Events 8-K 1 a15-2391418k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of incorporat |
|
| November 9, 2015 |
Exhibit 99.1 FOR FURTHER INFORMATION: Bill Hodges Nichol Ochsner Chief Financial Officer Executive Director, Investor Relations (919) 913-1030 & Corporate Communications (919) 913-1030 POZEN REPORTS THIRD QUARTER 2015 RESULTS -Strategic Merger with Tribute Pharmaceuticals Still on Track to Close in December 2015- -Commercial Launch Preparation Efforts for YOSPRALATM Well Underway- Chapel Hill, N.C |
|
| November 9, 2015 |
EXHIBIT 10.3 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (“ Agreement”) is made as of September 11, 2015, by and between POZEN Inc. (together with its successors and assigns, “ POZEN” or the “ Company”), and James Tursi, M.D. (“ Executive”). R E C I T A L S WHEREAS, the Company desires to employ Executive and Executive desires to be employed by the Company as the Chief Medic |
|
| November 9, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 a15-2259918k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of incorporati |
|
| November 9, 2015 |
Pozen POZEN INC 10-Q 9-30-2015 (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-31719 POZEN Inc. (Exact |
|
| November 9, 2015 |
POZEN Corporate Overview 3Q 2015 Financial Results November 9, 2015 Exhibit 99.2 POZEN Corporate Overview 3Q 2015 Financial Results November 9, 2015 This presentation contains forward-looking statements under applicable securities laws, including, but not limited to, statements related to the anticipated consummation of the business combination transaction among Aralez, POZEN and Tribute and the timing and benefits thereof, the anticipated equity and debt financin |
|
| November 6, 2015 |
EX-99.1 2 a15-225391ex99d1.htm EX-99.1 Exhibit 99.1 Filed pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to 14a-12 under the Securities Exchange Act of 1934, as amended Filing Person: POZEN Inc. Subject Company: Tribute Pharmaceuticals Canada Inc. Commission File No.: 000-31198 POZEN AND TRIBUTE ANNOUNCE EFFECTIVENESS OF REGISTRATION STATEMENT ON FORM |
|
| November 6, 2015 |
Financial Statements and Exhibits, Other Events 8-K 1 a15-2253918k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of incorporati |
|
| November 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| November 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of incorporation) (Commission File Number |
|
| November 6, 2015 |
Exhibit 99.1 Filed pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to 14a-12 under the Securities Exchange Act of 1934, as amended Filing Person: POZEN Inc. Subject Company: Tribute Pharmaceuticals Canada Inc. Commission File No.: 000-31198 POZEN AND TRIBUTE ANNOUNCE EFFECTIVENESS OF REGISTRATION STATEMENT ON FORM S-4 -POZEN Schedules Stockholder Meetin |
|
| October 30, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of incorporation) (Commission File Number |
|
| October 30, 2015 |
AMENDED AND RESTATED FACILITY AGREEMENT EX-10.1 2 a15-219581ex10d1.htm EX-10.1 Exhibit 10.1 AMENDED AND RESTATED FACILITY AGREEMENT This AMENDED AND RESTATED FACILITY AGREEMENT (this “Agreement”), dated as of October 29, 2015, by and among Stamridge Limited, a private limited liability company incorporated under the laws of the Republic of Ireland with company registration number 561897 being a wholly owned indirect Subsidiary of the Pa |
|
| October 30, 2015 |
AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT EX-10.2 3 a15-219581ex10d2.htm EX-10.2 Exhibit 10.2 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October 29, 2015, by and among Aralez Pharmaceuticals Limited, a private limited company incorporated in Ireland with company registration number 561617 (formerly known as Aguono Limited) (the “Company”), and |
|
| October 30, 2015 |
Financial Statements and Exhibits, Entry into a Material Definitive Agreement 8-K 1 a15-2195818k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 29, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of incorporati |
|
| October 30, 2015 |
AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT EX-10.2 3 a15-219581ex10d2.htm EX-10.2 Exhibit 10.2 AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT This AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of October 29, 2015, by and among Aralez Pharmaceuticals Limited, a private limited company incorporated in Ireland with company registration number 561617 (formerly known as Aguono Limited) (the “Company”), and |
|
| October 30, 2015 |
AMENDED AND RESTATED FACILITY AGREEMENT EX-10.1 2 a15-219581ex10d1.htm EX-10.1 Exhibit 10.1 AMENDED AND RESTATED FACILITY AGREEMENT This AMENDED AND RESTATED FACILITY AGREEMENT (this “Agreement”), dated as of October 29, 2015, by and among Stamridge Limited, a private limited liability company incorporated under the laws of the Republic of Ireland with company registration number 561897 being a wholly owned indirect Subsidiary of the Pa |
|
| September 28, 2015 |
“Strategic Rationale and Vision for Aralez Pharmaceuticals” September 2015 Exhibit 99.1 Strategic Rationale and Vision for Aralez Pharmaceuticals September 2015 This presentation contains forward-looking statements under applicable securities laws, including, but not limited to, statements related to the anticipated consummation of the business combination transaction among Aralez, POZEN and Tribute and the timing and benefits thereof, the anticipated equity and debt f |
|
| September 28, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events 8-K 1 a15-2027218k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of incorpora |
|
| September 28, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| September 28, 2015 |
“Strategic Rationale and Vision for Aralez Pharmaceuticals” September 2015 Exhibit 99.1 ?Strategic Rationale and Vision for Aralez Pharmaceuticals? September 2015 This presentation contains forward-looking statements under applicable securities laws, including, but not limited to, statements related to the anticipated consummation of the business combination transaction among Aralez, POZEN and Tribute and the timing and benefits thereof, the anticipated equity and debt f |
|
| September 14, 2015 |
8-K 1 form8k09142015.htm FORM 8-K 09 14 2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdi |
|
| August 10, 2015 |
“Strategic Rationale and Vision for Aralez Pharmaceuticals” August, 2015 Exhibit 99.1 ?Strategic Rationale and Vision for Aralez Pharmaceuticals? August, 2015 This presentation contains forward-looking statements under applicable securities laws, including, but not limited to, statements related to the anticipated consummation of the business combination transaction among Aralez, POZEN and Tribute and the timing and benefits thereof, the anticipated equity and debt fin |
|
| August 10, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 10, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| August 10, 2015 |
“Strategic Rationale and Vision for Aralez Pharmaceuticals” August, 2015 EX-99.1 2 a15-174011ex99d1.htm EX-99.1 Exhibit 99.1 “Strategic Rationale and Vision for Aralez Pharmaceuticals” August, 2015 This presentation contains forward-looking statements under applicable securities laws, including, but not limited to, statements related to the anticipated consummation of the business combination transaction among Aralez, POZEN and Tribute and the timing and benefits there |
|
| August 10, 2015 |
Financial Statements and Exhibits, Results of Operations and Financial Condition form8k08102015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 10, 2015 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| August 10, 2015 |
exhibit991.htm EXHIBIT 99.1 FOR FURTHER INFORMATION: Bill Hodges Nichol Ochsner Chief Financial Officer (919) 913-1030 Executive Director, Investor Relations & Corporate Communications (919) 913-1030 POZEN REPORTS SECOND QUARTER 2015 RESULTS -Strategic Merger with Tribute Pharmaceuticals Expected to Close in the 4Q 2015- -Commercialization Plans for YOSPRALATM Underway- Chapel Hill, N.C., August 1 |
|
| July 29, 2015 |
LIMITED POWER OF ATTORNEY FOR SECTION 16(a) REPORTING Exhibit 24 LIMITED POWER OF ATTORNEY FOR SECTION 16(a) REPORTING KNOW ALL PERSONS BY THESE PRESENTS, that the undersigned hereby makes, constitutes and appoints Gilda Thomas and John E. |
|
| July 27, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| July 27, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| July 27, 2015 |
“Strategic Rationale and Vision for Aralez Pharmaceuticals” July, 2015 Exhibit 99.1 ?Strategic Rationale and Vision for Aralez Pharmaceuticals? July, 2015 This presentation contains forward-looking statements under applicable securities laws, including, but not limited to, statements related to the anticipated consummation of the business combination transaction among Aralez, POZEN and Tribute and the timing and benefits thereof, the anticipated equity and debt finan |
|
| July 27, 2015 |
“Strategic Rationale and Vision for Aralez Pharmaceuticals” July, 2015 Exhibit 99.1 ?Strategic Rationale and Vision for Aralez Pharmaceuticals? July, 2015 This presentation contains forward-looking statements under applicable securities laws, including, but not limited to, statements related to the anticipated consummation of the business combination transaction among Aralez, POZEN and Tribute and the timing and benefits thereof, the anticipated equity and debt finan |
|
| July 27, 2015 |
form8k07272015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 27, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of incorporation) (Commis |
|
| July 20, 2015 |
Strategic Rationale and Vision for Aralez Pharmaceuticals July, 2015 Exhibit 99.1 ?Strategic Rationale and Vision for Aralez Pharmaceuticals? July, 2015 This presentation contains forward-looking statements under applicable securities laws, including, but not limited to, statements related to the anticipated consummation of the business combination transaction among Aralez, POZEN and Tribute and the timing and benefits thereof, the anticipated equity and debt finan |
|
| July 20, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| July 20, 2015 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events 8-K 1 a15-1589118k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of incorporation) |
|
| July 20, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 20, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 000-31719 (Commission File Number) 62-1657552 ( |
|
| July 20, 2015 |
8-K 1 a15-1589128k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 20, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 000-31719 (Commissio |
|
| July 20, 2015 |
“Strategic Rationale and Vision for Aralez Pharmaceuticals” July, 2015 Exhibit 99.1 ?Strategic Rationale and Vision for Aralez Pharmaceuticals? July, 2015 This presentation contains forward-looking statements under applicable securities laws, including, but not limited to, statements related to the anticipated consummation of the business combination transaction among Aralez, POZEN and Tribute and the timing and benefits thereof, the anticipated equity and debt finan |
|
| June 25, 2015 |
exhibit102.htm EXHIBIT 10.2 June , 2015 [Employee Name] [Employee Address] Re: Retention Bonus Agreement Dear [Employee Name], As you know, Pozen, Inc. (the ?Company?) is in the process of acquiring all of the outstanding equity of Tribute Pharmaceuticals Canada Inc. (the ?Transaction?). Due to your efforts to date and the important job duties you will have following the closing of the Transaction |
|
| June 25, 2015 |
POZEN INC. EMPLOYEE SEVERANCE PLAN SUMMARY PLAN DESCRIPTION JUNE 2015 exhibit101.htm EXHIBIT 10.1 POZEN INC. EMPLOYEE SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION JUNE 2015 TABLE OF CONTENTS Page I. INTRODUCTION 1 II. ELIGIBILITY 1 III. SEVERANCE BENEFITS 2 IV. CLAIMS PROCEDURE 3 V. STATEMENT OF RIGHTS UNDER THE EMPLOYEE RETIREMENT INCOME SECURITY ACT OF 1974 (?ERISA?) 4 VI. AMENDMENT AND TERMINATION 6 VII. EMPLOYMENT RIGHTS 6 VIII. NONALIENATION OF BENEFITS 6 IX. GO |
|
| June 25, 2015 |
form8k06252015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of incorporation) (Commis |
|
| June 15, 2015 |
Pozen FORM 8-K 06 15 2015 (Current Report/Significant Event) form8k06152015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 10, 2015 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission |
|
| June 11, 2015 |
Exhibit 10.1 FACILITY AGREEMENT FACILITY AGREEMENT (this ? Agreement?), dated as of June 8, 2015, between Borrower (hereinafter defined), POZEN Inc., a Delaware corporation (? Pozen?), Tribute Pharmaceuticals Canada Inc., an Ontario corporation (? Tribute?, and together with Borrower, Parent (hereinafter defined), to the extent that Irish Finco (hereinafter defined) is substituted for Parent as th |
|
| June 11, 2015 |
Pozen POZEN INC 8-K 6-8-2015 (Prospectus) 425 1 form8k.htm POZEN INC 8-K 6-8-2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of in |
|
| June 11, 2015 |
8-K 1 form8k.htm POZEN INC 8-K 6-8-2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 000-31719 62-1657552 (State or other jurisdiction of in |
|
| June 11, 2015 |
Exhibit 10.1 FACILITY AGREEMENT FACILITY AGREEMENT (this ? Agreement?), dated as of June 8, 2015, between Borrower (hereinafter defined), POZEN Inc., a Delaware corporation (? Pozen?), Tribute Pharmaceuticals Canada Inc., an Ontario corporation (? Tribute?, and together with Borrower, Parent (hereinafter defined), to the extent that Irish Finco (hereinafter defined) is substituted for Parent as th |
|
| June 11, 2015 |
Exhibit 2.1 Execution Copy AGREEMENT AND PLAN OF MERGER AND ARRANGEMENT AMONG TRIBUTE PHARMACEUTICALS CANADA INC., AGUONO LIMITED, TRAFWELL LIMITED, ARLZ US ACQUISITION CORP., ARLZ CA ACQUISITION CORP., AND POZEN INC. June 8, 2015 TABLE OF CONTENTS Page ARTICLE 1 INTERPRETATION 1 1.1 Definitions 1 1.2 Currency 14 1.3 Interpretation Not Affected by Headings 14 1.4 Knowledge and Disclosure 14 1.5 Ex |
|
| June 11, 2015 |
Exhibit 2.1 Execution Copy AGREEMENT AND PLAN OF MERGER AND ARRANGEMENT AMONG TRIBUTE PHARMACEUTICALS CANADA INC., AGUONO LIMITED, TRAFWELL LIMITED, ARLZ US ACQUISITION CORP., ARLZ CA ACQUISITION CORP., AND POZEN INC. June 8, 2015 TABLE OF CONTENTS Page ARTICLE 1 INTERPRETATION 1 1.1 Definitions 1 1.2 Currency 14 1.3 Interpretation Not Affected by Headings 14 1.4 Knowledge and Disclosure 14 1.5 Ex |
|
| June 3, 2015 |
EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.3 EXECUTION VERSION EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (? Agreement?) is made as of May 31, 2015, by and between POZEN Inc. (together with its successors and assigns, ? POZEN? or the ? Company?), and Adrian Adams (? Executive?). R E C I T A L S WHEREAS, the Company desires to employ Executive and Executive desires to be employed by the Company as the Comp |
|
| June 3, 2015 |
EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.4 EXECUTION VERSION EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (? Agreement?) is made as of May 31, 2015, by and between POZEN Inc. (together with its successors and assigns, ? POZEN? or the ? Company?), and Andrew Koven (? Executive?). R E C I T A L S WHEREAS, the Company desires to employ Executive and Executive desires to be employed by the Company as the Comp |
|
| June 3, 2015 |
As filed with the Securities and Exchange Commission on June 2, 2015 Registration No. |
|
| June 3, 2015 |
Exhibit 10.4 EXECUTION VERSION EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (? Agreement?) is made as of May 31, 2015, by and between POZEN Inc. (together with its successors and assigns, ? POZEN? or the ? Company?), and Andrew Koven (? Executive?). R E C I T A L S WHEREAS, the Company desires to employ Executive and Executive desires to be employed by the Company as the Comp |
|
| June 3, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2015 POZEN INC. (Exact name of registrant as specified in its charter) Delaware 001-31719 62-1657552 (State or other jurisdiction of incorporation) (Commission File Number) (I |
|
| June 3, 2015 |
SEPARATION AND GENERAL RELEASE AGREEMENT Exhibit 10.1 SEPARATION AND GENERAL RELEASE AGREEMENT This SEPARATION AND GENERAL RELEASE AGREEMENT (the ? Separation Agreement?) is made and entered into between POZEN Inc., a Delaware corporation (the ? Company?) and John R. Plachetka (? Executive?). Throughout the remainder of the Separation Agreement, the Company and Executive may be collectively referred to as ?the parties.? Executive is curr |
|
| June 3, 2015 |
Exhibit 99.1 POZEN ANNOUNCES RETIREMENT OF FOUNDER, CHAIRMAN AND CEO DR. JOHN R. PLACHETKA; ADRIAN ADAMS NAMED AS CEO CHAPEL HILL, N.C.?(BUSINESS WIRE)?June 1, 2015?POZEN Inc. (NASDAQ: ?POZN?), a pharmaceutical company committed to developing medicine that transforms lives, today announced that John R. Plachetka, Pharm.D., its founder, Chairman, Chief Executive Officer and President is retiring, e |
|
| June 3, 2015 |
Exhibit 99.1 POZEN ANNOUNCES RETIREMENT OF FOUNDER, CHAIRMAN AND CEO DR. JOHN R. PLACHETKA; ADRIAN ADAMS NAMED AS CEO CHAPEL HILL, N.C.?(BUSINESS WIRE)?June 1, 2015?POZEN Inc. (NASDAQ: ?POZN?), a pharmaceutical company committed to developing medicine that transforms lives, today announced that John R. Plachetka, Pharm.D., its founder, Chairman, Chief Executive Officer and President is retiring, e |
|
| June 3, 2015 |
Exhibit 10.2 VOTING AGREEMENT This VOTING AGREEMENT (this ? Agreement?), dated as of May 29, 2015, is made by and between Pozen Inc., a Delaware corporation (the ? Company?), and John R. Plachetka (the ? Stockholder?). WHEREAS, the Company and the Stockholder have entered into a Separation Agreement dated as of even date herewith (as such agreement may be subsequently amended or modified, the ? Se |
|
| June 3, 2015 |
Pozen POZEN INC DEFA 14A 6-2-2015 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| June 3, 2015 |
POZEN INC. INDUCEMENT AWARD RESTRICTED STOCK UNIT AGREEMENT EXHIBIT 10.1 June 2, 2015 POZEN INC. INDUCEMENT AWARD RESTRICTED STOCK UNIT AGREEMENT This INDUCEMENT AWARD RESTRICTED STOCK UNIT AGREEMENT (the ? Agreement?), dated as of June 2, 2015 (the ? Date of Grant?), is delivered by POZEN Inc. (? POZEN?), to (the ? Grantee?). RECITALS This Agreement provides for the grant of stock-based awards with respect to shares of common stock, par value $0.001 per s |
|
| June 3, 2015 |
SEPARATION AND GENERAL RELEASE AGREEMENT Exhibit 10.1 SEPARATION AND GENERAL RELEASE AGREEMENT This SEPARATION AND GENERAL RELEASE AGREEMENT (the ? Separation Agreement?) is made and entered into between POZEN Inc., a Delaware corporation (the ? Company?) and John R. Plachetka (? Executive?). Throughout the remainder of the Separation Agreement, the Company and Executive may be collectively referred to as ?the parties.? Executive is curr |
|
| June 3, 2015 |
Exhibit 10.2 VOTING AGREEMENT This VOTING AGREEMENT (this ? Agreement?), dated as of May 29, 2015, is made by and between Pozen Inc., a Delaware corporation (the ? Company?), and John R. Plachetka (the ? Stockholder?). WHEREAS, the Company and the Stockholder have entered into a Separation Agreement dated as of even date herewith (as such agreement may be subsequently amended or modified, the ? Se |
|
| June 3, 2015 |
Exhibit 10.3 EXECUTION VERSION EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (“ Agreement”) is made as of May 31, 2015, by and between POZEN Inc. (together with its successors and assigns, “ POZEN” or the “ Company”), and Adrian Adams (“ Executive”). R E C I T A L S WHEREAS, the Company desires to employ Executive and Executive desires to be employed by the Company as the Comp |
|
| May 22, 2015 |
Pozen FORM 8-K 05 22 2015 (Current Report/Significant Event) form8k05222015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 21, 2015 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 8, 2015 |
POZEN REPORTS FIRST QUARTER 2015 RESULTS exhibit991.htm EXHIBIT 99.1 FOR FURTHER INFORMATION: Bill Hodges Stephanie Bonestell Chief Financial Officer Manager, Investor Relations & Public Relations (919) 913-1030 (919) 913-1030 POZEN REPORTS FIRST QUARTER 2015 RESULTS Chapel Hill, N.C., May 8, 2015 — POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for th |
|
| May 8, 2015 |
Pozen FORM 8-K 05 08 2015 (Current Report/Significant Event) form8k05082015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 8, 2015 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 27, 2015 |
DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 27, 2015 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule |
|
| March 9, 2015 |
exhibit991.htm EXHIBIT 99.1 FOR FURTHER INFORMATION: Bill Hodges Stephanie Bonestell Chief Financial Officer Manager, Investor Relations & Public Relations (919) 913-1030 (919) 913-1030 POZEN REPORTS FOURTH QUARTER AND YEAR END 2014 RESULTS - Reports Annual Net Income of $19.7 Million, Including VIMOVO Royalty of $21.1 Million - - Updates Anticipated Commercialization Timing - Chapel Hill, N.C., M |
|
| March 9, 2015 |
Pozen FORM 8-K 03 09 2015 (Current Report/Significant Event) form8k03092015.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 9, 2015 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission |
|
| February 6, 2015 |
POZN / Pozen, Inc. S-3 - - POZEN INC S-3 2-6-2015 As filed with the Securities and Exchange Commission on February 6, 2015. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 POZEN INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 62-1657552 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer I |
|
| February 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 6, 2015 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| February 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 6, 2015 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| January 5, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 31, 2014 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| December 29, 2014 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 22, 2014 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| December 17, 2014 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 16, 2014 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| December 17, 2014 |
POZEN’S YOSPRALA™ RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA FOR FURTHER INFORMATION: Bill Hodges Stephanie Bonestell Chief Financial Officer Manager, Investor Relations & Public Relations (919) 913-1030 (919) 913-1030 POZEN’S YOSPRALA™ RECEIVES COMPLETE RESPONSE LETTER FROM THE FDA Chapel Hill, North Carolina – December 17, 2014 – POZEN Inc. |
|
| December 11, 2014 |
POZN / Pozen, Inc. / PAR INVESTMENT PARTNERS LP - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Pozen, Inc. (Name of Issuer) Common stock, par value $.01 (Title of Class of Securities) 73941U102 (CUSIP Number) December 1, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant t |
|
| December 1, 2014 |
EXHIBIT 99.1 FOR FURTHER INFORMATION: Bill Hodges Stephanie Bonestell Chief Financial Officer Manager, Investor Relations & Public Relations (919) 913-1030 (919) 913-1030 POZEN INC. AND SANOFI US MUTUALLY AGREE TO TERMINATE U.S. PARTNERSHIP FOR PA8140/PA32540 FDA Provides Preliminary Approval for Tradename ‘YOSPRALA’ Pending Approval of the PA8140/PA32540 NDA Chapel Hill, N.C., December 1, 2014 — |
|
| December 1, 2014 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 29, 2014 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| November 6, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 6, 2014 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| November 6, 2014 |
EXHIBIT 99.1 FOR FURTHER INFORMATION: Bill Hodges Stephanie Bonestell Chief Financial Officer Manager, Investor Relations & Public Relations (919) 913-1030 (919) 913-1030 POZEN REPORTS THIRD QUARTER 2014 RESULTS Reports Net Income of $6.8 million, Including VIMOVO Royalty of $5.5 million Chapel Hill, N.C., November 6, 2014 — POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transfor |
|
| August 20, 2014 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 20, 2014 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| August 7, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 7, 2014 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| July 16, 2014 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 16, 2014 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| July 1, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 1, 2014 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| June 26, 2014 |
Other Events - FORM 8-K 06 26 2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 26, 2014 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| June 9, 2014 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 4, 2014 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E |
|
| May 14, 2014 |
Entry into a Material Definitive Agreement - FORM 8-K 05 13 2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 13, 2014 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E |
|
| May 8, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 8, 2014 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Em |
|
| May 8, 2014 |
EXHIBIT 99.1 FOR FURTHER INFORMATION: Bill Hodges Stephanie Bonestell Chief Financial Officer Manager, Investor Relations & Public Relations (919) 913-1030 (919) 913-1030 POZEN REPORTS FIRST QUARTER 2014 RESULTS Net Income Increases to $2.9 Million on Rise in VIMOVO U.S. Royalty Chapel Hill, N.C., May 8, 2014 — POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine |
|
| April 28, 2014 |
EXHIBIT 99.1 FOR FURTHER INFORMATION: Bill Hodges Stephanie Bonestell Chief Financial Officer Manager, Investor Relations & Public Relations (919) 913-1030 (919) 913-1030 POZEN’S PA8140/PA32540 RECEIVES A COMPLETE RESPONSE LETTER FROM FDA CITING ISSUES AT A FACILITY OF A THIRD PARTY SUPPLIER OF AN ACTIVE INGREDIENT Chapel Hill, North Carolina – April 25, 2014 – POZEN Inc. (NASDAQ: POZN), a pharmac |
|
| April 28, 2014 |
Financial Statements and Exhibits, Other Events - FORM 8-K 04 25 2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 25, 2014 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| April 21, 2014 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 21, 2014 |
DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 18, 2014 |
EXHIBIT 99.1 Dear Stockholder: I am the Chairman of POZEN’s Compensation Committee and am writing to let you know that we value the input of our stockholders. Although the ‘say on pay’ proposal in our 2013 proxy was approved, a favorable vote of approximately 54% was not a level of approval acceptable to us. In 2013, the Compensation Committee commissioned a third party to contact institutional st |
|
| April 18, 2014 |
Financial Statements and Exhibits, Other Events - FORM 8-K 04 18 2014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 18, 2014 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| March 14, 2014 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 10, 2014 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| March 6, 2014 |
Pozen POZEN INC 10-K 12-31-2013 (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2013 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission file number 000-31719 POZEN INC. (Exact name o |
|
| March 5, 2014 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 26, 2014 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| March 5, 2014 |
EXHIBIT 99.1 FOR FURTHER INFORMATION: Bill Hodges Stephanie Bonestell Chief Financial Officer Manager, Investor Relations & Public Relations (919) 913-1030 (919) 913-1030 POZEN REPORTS FOURTH QUARTER & YEAR END 2013 RESULTS Company Confirms Strategic Goals of Maximizing Shareholder Value, Expense Control and Returning Excess Cash to Shareholders Chapel Hill, N.C., March 5, 2014 — POZEN Inc. (NASDA |
|
| March 5, 2014 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 5, 2014 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| February 21, 2014 |
Pozen FORM 10-Q AMENDMENT NO. 1 (Quarterly Report) 10-Q/A 1 d678769d10qa.htm FORM 10-Q AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q/A Amendment No. 1 x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transi |
|
| February 21, 2014 |
EX-10.2 2 d678769dex102.htm EX-10.2 EXHIBIT 10.2 THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [* * *] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. LICENSE AND COLLABORATION AGREEMENT by and between POZEN INC. and sanofi-aventis U.S. LLC September 3, 2013 THIS EXHIBIT HAS BEEN REDACTED AND IS TH |
|
| February 14, 2014 |
POZN / Pozen, Inc. / PAR INVESTMENT PARTNERS LP - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Pozen, Inc. (Name of Issuer) Common stock, par value $.01 (Title of Class of Securities) 73941U102 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 12, 2014 |
POZN / Pozen, Inc. / VANGUARD GROUP INC Passive Investment pozeninc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1 )* Name of issuer: Pozen Inc Title of Class of Securities: Common Stock CUSIP Number: 73941U102 Date of Event Which Requires Filing of this Statement: December 31, 2013 Check the appropriate box to designate the |
|
| January 9, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 6, 2014 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| January 9, 2014 |
SEVERANCE AGREEMENT In consideration of the benefits provided to the undersigned employee (“Employee”) set forth herein, Employee agrees as follows: 1. |
|
| January 2, 2014 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 1, 2014 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| January 2, 2014 |
EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), is entered into effective as of January 1, 2014 (the Effective Date”), by and between POZEN Inc. (the “Company”), with offices located at Suite 400, 1414 Raleigh Road, Chapel Hill, North Carolina 27517, and Dennis L. McNamara. (“Executive”), whose address is 111 Lone Pine Road, Chapel Hill, North Car |
|
| January 2, 2014 |
EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), is effective as of January 1, 2014 (the Effective Date”), by and between POZEN Inc. (the “Company”), with offices located at Suite 400, 1414 Raleigh Road, Chapel Hill, North Carolina 27517, and Dennis L. McNamara (“Executive”), whose address is 111 Lone Pine Road, Chapel Hill, North Carolina 27514. W |
|
| January 2, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K 01022014 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 1, 2014 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IR |
|
| December 23, 2013 |
Other Events - FORM 8-K 12 23 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 21, 2013 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| December 5, 2013 |
POZEN CLARIFIES EX-DIVIDEND DATE FOR PREVIOUSLY ANNOUNCED SPECIAL CASH DISTRIBUTION EX-99.1 2 exhibit991.htm EXHIBIT 99.1 EXHIBIT 99.1 FOR FURTHER INFORMATION: Bill Hodges Stephanie Bonestell Chief Financial Officer Manager, Investor Relations & Public Relations (919) 913-1030 (919) 913-1030 POZEN CLARIFIES EX-DIVIDEND DATE FOR PREVIOUSLY ANNOUNCED SPECIAL CASH DISTRIBUTION Chapel Hill, N.C., December 5, 2013 — POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to tran |
|
| December 5, 2013 |
Financial Statements and Exhibits, Other Events - FORM 8-K 12 05 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 5, 2013 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| November 21, 2013 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 21, 2013 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| November 21, 2013 |
EXHIBIT 99.1 FOR FURTHER INFORMATION: Bill Hodges Stephanie Bonestell Chief Financial Officer Manager, Investor Relations & Public Relations (919) 913-1030 (919) 913-1030 POZEN ANNOUNCES SPECIAL CASH DISTRIBUTION Return of $1.75 Per Share to All Stockholders of Record as of December 11, 2013 Chapel Hill, N.C., November 21, 2013 — POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to tra |
|
| November 19, 2013 |
Entry into a Material Definitive Agreement - FORM 8-K 11 18 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 18, 2013 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| November 6, 2013 |
EXHIBIT 99.1 FOR FURTHER INFORMATION: Bill Hodges Stephanie Bonestell Chief Financial Officer Manager, Investor Relations & Public Relations (919) 913-1030 (919) 913-1030 POZEN REPORTS THIRD QUARTER 2013 RESULTS Exclusive License Agreement for U.S. Rights to PA8140/PA32540 Signed with Sanofi US Chapel Hill, N.C., November 6, 2013 — POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to t |
|
| November 6, 2013 |
8-K 1 form8k11062013.htm FORM 8-K 11 06 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 6, 2013 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction |
|
| September 30, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 25, 2013 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| September 18, 2013 |
Entry into a Material Definitive Agreement, Other Events - FORM 8-K 09 16 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 16, 2013 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) |
|
| September 4, 2013 |
Entry into a Material Definitive Agreement - FORM 8-K 09 04 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 4, 2013 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| August 6, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 form8k08062013.htm FORM 8-K 08 06 2013 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 6, 2013 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of |
|
| August 6, 2013 |
POZEN REPORTS SECOND QUARTER 2013 RESULTS NDA for PA8140/PA32540 Accepted for Review by FDA EXHIBIT 99.1 FOR FURTHER INFORMATION: Bill Hodges Stephanie Bonestell Chief Financial Officer Manager, Investor Relations & Public Relations (919) 913-1030 (919) 913-1030 POZEN REPORTS SECOND QUARTER 2013 RESULTS NDA for PA8140/PA32540 Accepted for Review by FDA Chapel Hill, N.C., August 6, 2013 — POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transform |
|
| July 15, 2013 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 10, 2013 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| June 10, 2013 |
Submission of Matters to a Vote of Security Holders - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 6, 2013 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 10, 2013 |
POZN / Pozen, Inc. / PAR INVESTMENT PARTNERS LP - SC 13GA Passive Investment SC 13G/A 1 d537708dsc13ga.htm SC 13GA UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Pozen, Inc. (Name of Issuer) Common stock, par value $.01 (Title of Class of Securities) 73941U102 (CUSIP Number) April 18, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| May 8, 2013 |
POZEN REPORTS FIRST QUARTER 2013 RESULTS NDA for PA32540/PA8140 Submitted to FDA in Late March EXHIBIT 99.1 FOR FURTHER INFORMATION: Bill Hodges Stephanie Bonestell Chief Financial Officer Manager, Investor Relations & Public Relations (919) 913-1030 (919) 913-1030 POZEN REPORTS FIRST QUARTER 2013 RESULTS NDA for PA32540/PA8140 Submitted to FDA in Late March Chapel Hill, N.C., May 8, 2013 — POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transform |
|
| May 8, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 8, 2013 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Em |
|
| April 23, 2013 |
Definitive Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 23, 2013 |
- DEFINITIVE ADDITIONAL MATERIALS Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 15, 2013 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 13, 2013 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 6, 2013 |
Regulation FD Disclosure - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 6, 2013 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 6, 2013 |
EXHIBIT 99.1 FOR FURTHER INFORMATION: Bill Hodges Stephanie Bonestell Chief Financial Officer Manager, Investor Relations & Public Relations (919) 913-1030 (919) 913-1030 POZEN REPORTS FOURTH QUARTER & YEAR END 2012 RESULTS NDA Filing for PA32540/PA8140 Expected by Q2 2013 Chapel Hill, N.C., March 6, 2013 — POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that |
|
| March 6, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 6, 2013 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| March 4, 2013 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 27, 2013 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| February 27, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 26, 2013 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| February 14, 2013 |
POZN / Pozen, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* POZEN Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 73941U102 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 13, 2013 |
POZN / Pozen, Inc. / VANGUARD GROUP INC Passive Investment pozeninc.htm - Generated by SEC Publisher for SEC Filing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 0 )* Name of issuer: Pozen Inc Title of Class of Securities: Common Stock CUSIP Number: 73941U102 Date of Event Which Requires Filing of this Statement: December 31, 2012 Check the appropriate box to designate the |
|
| February 12, 2013 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 12, 2013 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 12, 2013 |
EX-99.1 BIO CEO & Investor Conference February 2013 Exhibit 99.1 Forward-Looking Statements 2 The following presentation includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are |
|
| December 7, 2012 |
Correspondence POZEN INC. 1414 Raleigh Road, Suite 400 Chapel Hill, North Carolina 27517 December 7, 2012 VIA EDGAR AND FAX Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Judiciary Plaza Washington, D.C. 20549 Mail Stop 3010 Attention: Jim B. Rosenberg, Senior Assistant Chief Accountant Re: POZEN Inc. Form 10-K for the Fiscal Year Ended December 31, 2011 File |
|
| November 28, 2012 |
Other Events - FORM 8-K 11 21 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 21, 2012 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| November 15, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K 11 15 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 15, 2012 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| November 15, 2012 |
EXHIBIT 99.1 FOR FURTHER INFORMATION: Bill Hodges Stephanie Bonestell Chief Financial Officer Manager, Investor Relations & Public Relations (919) 913-1030 (919) 913-1030 POZEN ANNOUNCES POSITIVE RESULTS FOR THE PA8140-102 BIOAVAILABILITY STUDY NDA Filing Planned for April 2013 Chapel Hill, N.C., November 15, 2012 — POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medi |
|
| November 8, 2012 |
POZEN REPORTS THIRD QUARTER 2012 FINANCIAL RESULTS AND POSITIVE PA32540 CLINICAL UPDATES EXHIBIT 99.1 FOR FURTHER INFORMATION: Bill Hodges Stephanie Bonestell Chief Financial Officer Manager, Investor Relations & Public Relations (919) 913-1030 (919) 913-1030 POZEN REPORTS THIRD QUARTER 2012 FINANCIAL RESULTS AND POSITIVE PA32540 CLINICAL UPDATES Chapel Hill, N.C., November 8, 2012 — POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms |
|
| November 8, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 8, 2012 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| November 1, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 1, 2012 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| October 25, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 25, 2012 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| October 22, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 19, 2012 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I |
|
| August 23, 2012 |
Financial Statements and Exhibits, Other Events 8-K 1 form8k08212012.htm FORM 8-K 08 21 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 21, 2012 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction o |
|
| August 23, 2012 |
POZEN PROVIDES UPDATE ON ITS PA PROGRAM AND RESULTS OF ITS TYPE A MEETING WITH THE FDA EXHIBIT 99.1 FOR FURTHER INFORMATION: Bill Hodges Stephanie Bonestell Chief Financial Officer Manager, Investor Relations & Public Relations (919) 913-1030 (919) 913-1030 POZEN PROVIDES UPDATE ON ITS PA PROGRAM AND RESULTS OF ITS TYPE A MEETING WITH THE FDA Chapel Hill, N.C., August 23, 2012 — POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms li |
|
| August 1, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 1, 2012 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| August 1, 2012 |
POZEN REPORTS PA32540 / PA8140 UPDATES AND SECOND QUARTER 2012 FINANCIAL RESULTS FOR FURTHER INFORMATION: Bill Hodges Stephanie Bonestell Chief Financial Officer Manager, Investor Relations & Public Relations (919) 913-1030 (919) 913-1030 POZEN REPORTS PA32540 / PA8140 UPDATES AND SECOND QUARTER 2012 FINANCIAL RESULTS Chapel Hill, N. |
|
| June 20, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K 06 18 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 15, 2012 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS |
|
| June 20, 2012 |
POZEN ANNOUNCES FDA RESPONSE TO ITS PHASE 1, PA32540 BIOEQUIVALENCE STUDY ANALYSES EXHIBIT 99.1 FOR FURTHER INFORMATION: Bill Hodges Stephanie Bonestell Chief Financial Officer Manager, Investor Relations & Public Relations (919) 913-1030 (919) 913-1030 POZEN ANNOUNCES FDA RESPONSE TO ITS PHASE 1, PA32540 BIOEQUIVALENCE STUDY ANALYSES Chapel Hill, N.C., June 20, 2012 — POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, t |
|
| June 11, 2012 |
Submission of Matters to a Vote of Security Holders - FORM 8-K 06 07 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 7, 2012 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS E |
|
| May 9, 2012 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 7, 2012 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Em |
|
| May 1, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 1, 2012 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number |
|
| May 1, 2012 |
POZEN REPORTS PA32540 / PA8140 UPDATES AND FIRST QUARTER 2012 FINANCIAL RESULTS Press Release Exhibit 99.1 FOR FURTHER INFORMATION: Bill Hodges Stephanie Bonestell Chief Financial Officer Manager, Investor Relations & Public Relations (919) 913-1030 (919) 913-1030 POZEN REPORTS PA32540 / PA8140 UPDATES AND FIRST QUARTER 2012 FINANCIAL RESULTS Chapel Hill, N.C., May 1, 2012 — POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms |
|
| April 26, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 23, 2012 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| April 24, 2012 |
- DEFINITIVE ADDITIONAL MATERIALS Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 24, 2012 |
DEF 14A 1 d333708ddef14a.htm DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Co |
|
| March 22, 2012 |
Financial Statements and Exhibits, Other Events 8-K 1 form8k03222012.htm FORM 8-K 03 22 2012 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 22, 2012 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of |
|
| March 22, 2012 |
FOR FURTHER INFORMATION: Bill Hodges Stephanie Bonestell Chief Financial Officer Manager, Investor Relations & Public Relations (919) 913-1030 (919) 913-1030 POZEN ANNOUNCES POSITIVE TOP-LINE RESULTS FROM TWO PIVOTAL PHASE 3 STUDIES OF PA32540 New Drug Application Submission Anticipated in Q3 2012 Detailed Results to be Submitted for Journal Publication and Presentation at a Future Scientific Meeting Chapel Hill, N. |
|
| March 22, 2012 |
8-K 1 form8k03222012a.htm FORM 8-K 03 22 2012 A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 16, 2012 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction |
|
| March 16, 2012 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 13, 2012 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| February 28, 2012 |
EX-99.1 2 exhibit991.htm EXHIBIT 99.1 FOR FURTHER INFORMATION: Bill Hodges Stephanie Bonestell Chief Financial Officer Manager, Investor Relations & Public Relations (919) 913-1030 (919) 913-1030 POZEN REPORTS FOURTH QUARTER & YEAR END 2011 RESULTS Chapel Hill, N.C., February 28, 2012 — POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, to |
|
| February 28, 2012 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): February 28, 2012 POZEN INC. (Exact Name of Registrant as Specified in Charter) Delaware 000-31719 62-1657552 (State or Other Jurisdiction of Incorporation) (Commission File Number) ( |
|
| February 17, 2012 |
Acceleration Request POZEN INC. 1414 Raleigh Road, Suite 400 Chapel Hill, North Carolina 27517 (919) 913-1030 February 17, 2012 VIA FACSIMILE & EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jeffrey P. Riedler, Assistant Director Re: POZEN Inc. Registration Statement on Form S-3 (File Number 333-178673) Dear Mr. Riedler |
|
| February 14, 2012 |
POZN / Pozen, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13GA Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* POZEN Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 73941U102 (CUSIP Number) January 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 13, 2012 |
POZN / Pozen, Inc. / Allianz Global Investors U.S. LLC - SC 13G/A Passive Investment SC 13G/A OMB APPROVAL OMB Number: 3235-0145 Estimated average burden hours per response ………… 10. |
|
| January 24, 2012 |
As filed with the Securities and Exchange Commission on January 24, 2012. Registration No. 333-178673 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 POZEN INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 62-1657552 (State or Other Jurisdiction of Incorporation or Organiz |
|
| January 24, 2012 |
POZEN INC. 1414 Raleigh Road, Suite 400 Chapel Hill, North Carolina 27517 January 24, 2012 VIA EDGAR AND FAX Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Judiciary Plaza Washington, D.C. 20549 Mail Stop 3010 Attention: Jeffrey Riedler, Assistant Director Re: POZEN Inc. Registration Statement on Form S-3 Filed December 21, 2011 File No. 333-178673 Dear Mr. R |
